Bayer: Science For A Better Life

United States of America

CFG - ReDOS

Call For Grant 

Budget: $125,000

Intended Audience:

  • Community Oncologist
  • Community PAs
  • Community Nurses
  • Community Pharmacist 

Bayer TA Rationale for Educational Support:

  • Maximizing treatment benefit in 3rd line mCRC patients
    • Alternative dose optimization strategies
    • Impact of duration of treatment on outcomes
  • AE management strategies in 3rd line mCRC:
    • AE monitoring strategies
    • AE prophylaxis/treatment strategies

Preferred Format:  

  • Enduring
  • Downloadable slides
  • Podcast
  • Virtual

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).
The proposal should include:

  • Needs assessment
  • Educational design and rationale for selection (where applicable)
  • Learning Objectives & Draft Agenda
  • Proposed Faculty
  • Participant recruitment plan (where applicable)
  • Outcomes strategy/plan
  • Detailed budget (please use the template available on the website)

Provider Justification:

Copy of most recent accreditation letter and status

Process:

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will: 

  • Provide timely updates on changes in project timeline and event launch date
  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs
  • Share activity data and outcomes metrics within 30 days of their availability
     

References:

 

  1. Hatori M, et al. “Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting. Dose Response.” 2021 Oct 12;19(4):15593258211047658. (link)
  2. Yeh KH, et al. “Real- world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan.” J Formos Med Assoc. 2021 Nov;120(11):2023-2031. Epub 2021 Jan 7. (link)
  3. Hofheinz, R et al. “Effect of regorafenib in delaying definitive deterioration in health-related quality of life across three tumor types.” Annals of Oncology 30 (4), July 2019 (link)
  4. Bekaii-Saab, TS et al. “Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.” Lancet Oncology 2019 Aug;20(8):1070-1082. (link)
  5. Sato, J et al. “Adherence to a topical moisturizing preparation for regorafenib-related hand-foot skin reaction.” J Oncol Pharm Pract. 2019 May 19:1078155219849275. (link)
  6. Røed Skårderud M, et al. “Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.” Cancer Treat Rev. 2018 Jan;62:61-73. Epub 2017 Nov 10. (link)
  7. Yoon SE, et al. “The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice.” Onco Targets Ther. 2018 Dec 24;12:225-231. (link)
  8. Grothey A, et al.  “Current Options for Third-Line Treatment of Metastatic Colorectal Cancer.” Clin Adv Hematol Oncol. 2016 Mar;14(3 Suppl 3):1-15. (link)
  9. Grothey A. “Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.” Clin Adv Hematol Oncol. 2015 Aug;13(8):514-7. (link)